首页> 外文期刊>Cardiovascular revascularization medicine: including molecular interventions >Transcatheter Mitral Valve Repair with MitraClip for Severe Mitral Regurgitation and Cardiogenic Shock During the COVID-19 Pandemic
【24h】

Transcatheter Mitral Valve Repair with MitraClip for Severe Mitral Regurgitation and Cardiogenic Shock During the COVID-19 Pandemic

机译:在Covid-19大流行期间,具有Mitraclip的经截面二尖瓣修复,用于严重二尖瓣反流和心肌休克

获取原文
获取原文并翻译 | 示例
           

摘要

Transcatheter mitral valve repair with MitraClip (Abbott) is largely an elective procedure. The ongoing coronavirus disease 2019 (COVID-19) pandemic has posed challenges to health care systems; in many cases elective interventions have been curtailed. Patients with severemitral regurgitation (MR) and cardiogenic shock are high-risk surgical candidates and at risk of a poor outcome without intervention. The American College of Cardiology (ACC) and the Society of Coronary Angiography and Interventions (SCAI) recently proposed joint guidance on triage of structural heart disease (SHD) interventions during the COVID-19 pandemic. We present two illustrative cases of severe MR and cardiogenic shock that were successfully treated with MitraClip amidst the COVID-19 pandemic with good outcomes at short term follow-up. (c) 2020 Elsevier Inc. All rights reserved.
机译:经导管二尖瓣修补术(Abbott)在很大程度上是一种选择性手术。正在进行的2019年冠状病毒病(COVID-19)大流行对卫生保健系统构成了挑战;在许多情况下,选择性干预措施被削减。重度返流(MR)和心源性休克的患者是高风险的外科候选者,在不进行干预的情况下有可能出现不良结果。在2019冠状病毒疾病的治疗中,美国心脏病学会(ACC)和冠状动脉造影和介入学会(SCAI)最近提出了联合指导指导心脏病(SVD)介入治疗。我们提出两个2019冠状病毒疾病成功的短期治疗方案,并在治疗后的短期随访中成功地应用MITRACLIP治疗。(c) 2020爱思唯尔公司版权所有。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号